文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram.

作者信息

Wu Junyun, Deng Zhixuan, Lei Xu, Xu Zhiyao, Tan Chenxi, Tang Yunqiao, Sheng Xi, Yang Ning

机构信息

The Second Affiliated Hospital of University of South China, Hengyang, Hunan, China.

Institute of Cell Biology, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

出版信息

Front Oncol. 2025 Feb 3;15:1406585. doi: 10.3389/fonc.2025.1406585. eCollection 2025.


DOI:10.3389/fonc.2025.1406585
PMID:39963109
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11830596/
Abstract

PURPOSE: To investigate the impact of the product of preoperative platelet count and C-reactive protein (P-CRP) on the postoperative prognosis of patients with non-muscle invasive bladder cancer (NMIBC), and to construct a Nomogram to predict the recurrence-free survival (RFS) of NMIBC patients based on pathological data. METHODS: A retrospective analysis was conducted on the clinical data of 164 NMIBC patients who underwent transurethral resection of bladder tumors (TURBT) at the Second Affiliated Hospital of University of South China from January 2013 to December 2019. The endpoint of the study was the RFS. Kaplan-Meier (KM) method and Cox regression were used for analysis to identify independent factors affecting RFS. Then, the Nomogram was used to visualize the results of the multivariate analysis that were statistically significant and related to the RFS of NMIBC patients. Finally, the predictive ability of the model was evaluated using the concordance index (C-index) and calibration curves. RESULTS: Before the end of the follow-up, the RFS was 88.3% at 1 year, 75.5% at 2 years, and 58.5% at 3 years. KM curves showed that P-CRP (HR=0.357, 95% CI: 0.204-0.625, P<0.001), number of tumors (HR=2.658, 95% CI: 1.572-4.494, P<0.001), tumor size (HR=2.271, 95% CI: 1.377-3.745, P=0.001), T stage of the tumor (HR=2.026, 95% CI: 1.233-3.329, P=0.005), and tumor G grade (G2: HR=1.615, 95% CI: 0.48-5.433, G3: HR=3.361, 95% CI: 1.022-11.054) were independent factors affecting the RFS of NMIBC patients after TURBT. The Nomogram could estimate the risk of tumor recurrence at 1, 2, and 3 years postoperatively. The Nomogram model incorporating P-CRP parameters had a higher predictive accuracy than the classic model that only included EORTC risk group parameters. CONCLUSION: Preoperative P-CRP has a certain impact on the RFS of NMIBC patients after TURBT. The Nomogram incorporating P-CRP, number of tumors, tumor size, T stage, and tumor pathological grading can better predict the postoperative recurrence risk of NMIBC patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/e1db8f2c9366/fonc-15-1406585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/9182686fdfd4/fonc-15-1406585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/378d82bfed03/fonc-15-1406585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/fafb59a77a55/fonc-15-1406585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/6c2779e90977/fonc-15-1406585-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/f911c1143445/fonc-15-1406585-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/52b0c7022089/fonc-15-1406585-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/e1db8f2c9366/fonc-15-1406585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/9182686fdfd4/fonc-15-1406585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/378d82bfed03/fonc-15-1406585-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/fafb59a77a55/fonc-15-1406585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/6c2779e90977/fonc-15-1406585-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/f911c1143445/fonc-15-1406585-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/52b0c7022089/fonc-15-1406585-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78f1/11830596/e1db8f2c9366/fonc-15-1406585-g007.jpg

相似文献

[1]
Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram.

Front Oncol. 2025-2-3

[2]
Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score.

Cancer Manag Res. 2021-8-16

[3]
Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intravesical BCG instillation.

Front Oncol. 2023-7-5

[4]
Preoperative prognostic nutritional index and nomogram predicting recurrence-free survival in patients with primary non-muscle-invasive bladder cancer without carcinoma in situ.

Onco Targets Ther. 2017-11-21

[5]
The prognostic impact of tumor location in nonmuscle-invasive bladder cancer patients undergoing transurethral resection: insights from a cohort study utilizing Chinese multicenter and SEER registries.

Int J Surg. 2024-9-1

[6]
Development and external validation of a model to predict recurrence in patients with non-muscle invasive bladder cancer.

Front Immunol. 2025-1-10

[7]
Analysis of Risk Factors for Recurrence after Transurethral Resection of Bladder Tumor in Patients with Non-Muscle Invasive Bladder Cancer: 2-Year Follow-Up Outcomes.

Oncology. 2024

[8]
Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study.

BMC Cancer. 2024-10-8

[9]
The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer.

Int J Biol Markers. 2024-9

[10]
Preoperative systemic immune-inflammation index as a significant prognostic factor after TURBT in patients with non-muscle-invasive bladder cancer: A retrospective study based on propensity score matching analysis.

Cancer Med. 2023-3

本文引用的文献

[1]
Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis.

EBioMedicine. 2024-2

[2]
The dynamic role of platelets in cancer progression and their therapeutic implications.

Nat Rev Cancer. 2024-1

[3]
Bladder cancer.

Nat Rev Dis Primers. 2023-10-26

[4]
C-Reactive Protein Signaling Pathways in Tumor Progression.

Biomol Ther (Seoul). 2023-9-1

[5]
Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?

Niger J Clin Pract. 2023-5

[6]
Inflammation-related research within the field of bladder cancer: a bibliometric analysis.

Front Oncol. 2023-6-7

[7]
The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.

Qual Life Res. 2023-8

[8]
Inflammatory factors and restless legs syndrome: A systematic review and meta-analysis.

Sleep Med Rev. 2023-4

[9]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[10]
Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.

Int J Mol Sci. 2022-12-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索